Xilio Therapeutics, Inc.
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies for people with cancer. Its platform uses protein engineering to design biologics intended to remain inactive until tumor-specific proteases activate them in the tumor microenvironment. The pipeline includes XTX501, a bispecific PD-1 and masked IL-2; masked T cell engager programs targeting PSMA and STEAP1 and CLDN18.2; efarindodekin alfa, a masked IL-12 in a Phase 2 trial; and vilastobart, a masked anti-CTLA-4 antibody. Xilio develops programs on its own and through collaborations, including with AbbVie and Gilead. Its business centers on discovering and developing therapies, with programs also licensed or subject to collaboration and option agreements. Xilio Therapeutics is headquartered in Waltham, Massachusetts.
No SEC Form 4 filings for $XLO in the last 30 days.
See all $XLO insider activity →Xilio Therapeutics reported Q3 GAAP EPS of -$0.30, beating estimates by $0.64. Revenue was $9.98M, down 47.7% year-over-year but exceeding expectations by $5.06M. The company's performance may impact investor sentiment.
Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan
Xilio Therapeutics (XLO) has dosed the first patient in a Phase 1/2 trial for XTX501, a treatment for metastatic NSCLC after prior anti-PD(L)-1 therapy. The company expects initial Phase 1 data in Q4 2027, according to the press release.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning XLO (Xilio Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 5 bearish.
Recent XLO coverage spans financial news, earnings and corporate actions.
Earnings beat may drive short-term buying pressure.
The filing provides fresh earnings numbers and a key clinical milestone, offering new data for traders.
First-in-human dosing is a positive catalyst that may lift sentiment, but impact is limited until data emerge.
Analyst initiation and target raise may drive buying interest and price appreciation.
FDA IND clearance is a concrete de-risking step and sets a near-term clinical start timeline, which can re-rate risk for XLO.
AlphAI scores every news story that mentions XLO with an AI model for sentiment and relevance, and aggregates insider trades from Xilio Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Xilio Therapeutics reported Q3 GAAP EPS of -$0.30, beating estimates by $0.64. Revenue was $9.98M, down 47.7% year-over-year but exceeding expectations by $5.06M. The company's performance may impact investor sentiment.
Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan
Xilio Therapeutics (XLO) has dosed the first patient in a Phase 1/2 trial for XTX501, a treatment for metastatic NSCLC after prior anti-PD(L)-1 therapy. The company expects initial Phase 1 data in Q4 2027, according to the press release.
Raymond James initiated coverage on Xilio Therapeutics (NASDAQ:XLO) with an Outperform rating and a $16 price target, citing its masking technology and financial outlook. The stock trades at $8.54, with a market cap of $56.19M. Analysts note cash burn and clinical hurdles but see potential in collaborations and pipeline investments.
Xilio Therapeutics (XLO) reported Q2 2026 results and said the FDA cleared its IND for XTX501, enabling a Phase 1/2 trial. The company expects to start dosing in 2H 2026 and report initial NSCLC Phase 1 data in 2H 2027. Q2 revenue was $18.7M vs $8.1M; net loss was $6.4M. Cash was $136.0M.
Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential firs
Xilio Therapeutics (Nasdaq: XLO) said it granted 107,060 non-qualified stock options to three new employees effective July 1, 2026 under its 2022 Inducement Stock Incentive Plan. Options have a $9.22 exercise price, 10-year term, and vest 25% after one year then 75% monthly over 36 months, subject to continued service.
Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001840233 0001840233 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10,
Xilio Therapeutics (Nasdaq: XLO) has appointed Cheryl R. Blanchard, Ph.D., a biotech veteran with over 30 years of experience, to its board of directors, effective April 16, 2026. Dr. Blanchard's expertise in biologics, devices, and commercial strategy, including her current role as executive chair of Anika, is expected to support Xilio's masked immuno-oncology pipeline. This appointment follows the departure of Christina Rossi from the board on April 15, 2026.
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden ...
